Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice

Chinese Medical Journal

Volumn 122, Issue 19, 2009, Pages 2366-2371

  Ren, Jin Peng ^a   Zhao, Yu Wu ^a   Sun, Xiao Jiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Dopamine transporter; Oxidative stress; Paraquat; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MESSENGER RNA; PARAQUAT; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PROTEIN CONTENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; SUBSTANTIA NIGRA;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTATHIONE PEROXIDASE; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PARAQUAT; PARKINSON DISEASE; RNA, MESSENGER; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE;

EID: 70350590969     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.19.032     Document Type: Article

References (30)

1. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidem 1998; 17: 310-317. (Pubitemid 28482049)
2. Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J Neurosci 2007; 27: 6914-6922. (Pubitemid 47015904)
3. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997; 48: 1583-1588. (Pubitemid 27290768)
4. Dinis-Oliveira RJ, Remião F, Carmo H, Duarte JA, Navarro AS, Bastos ML, et al. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 2006; 27: 1110-1122. (Pubitemid 44838957)
5. Di Monte DA. The role of environmental agents in Parkinson's disease. Clin Neurosci Res 2001; 1: 419-426. (Pubitemid 33665560)
6. Abe K, Taguchi K, Wasai T. Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse. Brain Res 2001; 907: 134-138.
7. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 2000; 873: 225-234.
8. Li X, Yin J, Cheng CM, Sun JL, Li Z, Wu YL. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice. Chin Med J 2005; 118: 1357-1361. (Pubitemid 41223172)
9. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002; 277: 1641-1644. (Pubitemid 34968732)
10. Kang MJ, Gil SJ, Koh HC. Paraquat induces alternation of the dopamine catabolic pathways and glutathione levels in the substantia nigra of mice. Toxicol Lett 2009; 188: 148-152.
11. Rojo AI, Cavada C, de Sagarra MR, Cuadrado A. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Exp Neurol 2007; 208: 120-126. (Pubitemid 47600154)
12. Widdowson PS, Farnworth MJ, Upton R, Simpson MG. No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple paraquat administration to rats. Hum Exp Toxicol 1996; 15: 583-591. (Pubitemid 26259601)
13. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53 Suppl 3: s26-s36; discussion s36-s38.
14. Foley P, Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neuro1 2000; 247 Suppl 2: II82-II94.
15. Miller GW, Gainetdinov RR, Levey AI, Caron MG. Dopamine transporters and neuronal injury. Tips 1999; 20: 424-429.
16. Counihan TJ, Penney JB Jr. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. J Neurol Neurosurg Psychiatry 1998; 65: 164-169.
17. Asakura W, Matsumoto K, Ohta H, Watanabe H. Effects of alpha 2-adrenergic drugs on REM sleep deprivation induced increase in swimming activity. Pharmacol Biochem Behav 1993; 46: 111-115. (Pubitemid 223044727)
18. Nagatsu T. Changes of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity. Neurochem Res 1996; 15: 425-429.
19. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 1998; 95: 7659-7663.
20. Dodd CA, Klein BG. Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatum. Toxicol Ind Health 2009; 25: 25-39.
21. Pong K. Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics. Expert Opin Biol Ther 2003; 3: 127-139. (Pubitemid 36193657)
22. Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo 1999; 13: 295-309.
23. Kocaturk PA, Akbostanci MC, Tan F, Kavas GO. Superoxide dismutase activity and zinc and copper concentrations in Parkinson's disease. Pathophysiology 2000; 7: 63-67. (Pubitemid 30313000)
24. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 2008; 25: 49-52.
25. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997; 41: 530-539. (Pubitemid 27169193)
26. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004; 55: 766-773. (Pubitemid 38702571)
27. Chen P, Li A, Zhang M, He M, Chen Z, Wu X, et al. Protective effects of a new metalloporphyrin on paraquat-induced oxidative stress and apoptosis in N27 cells. Acta Biochim Biophys Sin 2008; 40: 125-132.
28. Miller RL, Sun GY, Sun AY. Cytotoxicity of paraquat in microglial cells: Involvement of PKCdelta- and ERK1/2-dependent NADPH oxidase. Brain Res 2007; 1167: 129-139.
29. Yang W, Tiffany-Castiglioni E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. J Toxicol Environ Health A 2005; 68: 1939-1961. (Pubitemid 41765788)
30. Tawara T, Fukushima T, Hojo N, Isobe A, Shiwaku K, Setogawa T, et al. Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain. Arch Toxicol 1996; 70: 585-589. (Pubitemid 26226682)